Cancer Research · 2017 · 165 citations · 33 references
MedicineOncologyRadiation OncologyCarcinogenesisMolecular OncologyTumor MicroenvironmentCancer Cell SignalingCancer MetabolismCancer MetabolomicsCancer-associated FibroblastsColorectal CancerMetabolic ReprogrammingCancer Signaling PathwaysCancer-associated Fibroblast MetabolismCancer-associated Fibroblast SignalingDamage-induced Transcriptional ResponsesDna Damage InductionDna Damage ResponsesGlutamine MetabolismInsulin-like Growth Factor-1
Abstract Preoperative radiotherapy (RT) is a mainstay in the management of rectal cancer, a tumor characterized by desmoplastic stroma containing cancer-associated fibroblasts (CAF). Although CAFs are abundantly present, the effects of RT to CAF and its impact on cancer cells are unknown. We evaluated the damage responses of CAF to RT and investigated changes in colorectal cancer cell growth, transcriptome, metabolome, and kinome in response to paracrine signals emerging from irradiated CAF. RT to CAF induced DNA damage, p53 activation, cell-cycle arrest, and secretion of paracrine mediators, including insulin-like growth factor-1 (IGF1). Subsequently, RT-activated CAFs promoted survival of colorectal cancer cells, as well as a metabolic switch favoring glutamine consumption through IGF1 receptor (IGF1R) activation. RT followed by IGF1R neutralization in orthotopic colorectal cancer models reduced the number of mice with organ metastases. Activation of the downstream IGF1R mediator mTOR was significantly higher in matched (intrapatient) samples and in unmatched (interpatient) samples from rectal cancer patients after neoadjuvant chemoradiotherapy. Taken together, our data support the notion that paracrine IGF1/IGF1R signaling initiated by RT-activated CAF worsens colorectal cancer progression, establishing a preclinical rationale to target this activation loop to further improve clinical responses and patient survival. Significance: These findings reveal that paracrine IGF1/IGF1R signaling promotes colorectal cancer progression, establishing a preclinical rationale to target this activation loop. Cancer Res; 78(3); 659–70. ©2017 AACR.
33
Rebecca L. Siegel, Kimberly D. Miller, Ahmedin Jemal · CA A Cancer Journal for Clinicians · 2016 · 16.2K citations · Full text
Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Bengt Glimelius, Emmanuel Tiret, Andrés Cervantes et al. · Annals of Oncology · 2013 · 1.8K citations · Full text
Stromal contribution to the colorectal cancer transcriptome
Claudio Isella, Andrea Terrasi, Sara E. Bellomo et al. · Nature Genetics · 2015 · 660 citations · Full text
Medicine, Cancer Biology, Oncology +14
Therapy-induced tumour secretomes promote resistance and tumour progression
Anna C. Obenauf, Yilong Zou, Andrew L. Ji et al. · Nature · 2015 · 502 citations · Full text
Medicine, Cancer Biology, Oncology +12
Selection of Bone Metastasis Seeds by Mesenchymal Signals in the Primary Tumor Stroma
Xiang H.-F. Zhang, Srinivas Malladi, Yilong Zou et al. · Cell · 2013 · 420 citations · Full text
Medicine, Cancer Biology, Oncology +16